Amylyx Pharmaceuticals, Inc. AMLX
30.31 USD -1.50 (-4.70%)
Nov 12, 2026, 3:13 PM EST
30.31 Day range 30.31
10.83 52-week range 41.14
- YTD
- +150.87%
- 1 year
- +145.78%
News
benzinga.com Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39 Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $38 to $39.
defenseworld.net Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…- defenseworld.net Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…
seekingalpha.com Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical…
marketbeat.com Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…- benzinga.com Amylyx Pharma Q3 EPS $(0.38), Inline Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate. This is a 2.7 percent decrease over losses of $(0.37) per share from the same…
businesswire.com Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.
benzinga.com Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39 Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
benzinga.com Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
benzinga.com Amylyx Pharma Q2 2026 Earnings Call Transcript Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
benzinga.com Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57 Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
benzinga.com Benzinga Bulls and Bears: Ross, Moderna, Webull Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
benzinga.com Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42 Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
benzinga.com Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55 Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.- benzinga.com Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52 Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
benzinga.com Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.- benzinga.com HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55 HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals…
benzinga.com Crude Oil Gains 1%; US Pending Home Sales Fall In July US stocks fell in midday trading, with S&P 500 down 0.5% and Dow dropping 0.17%. Health care shares rose 1.6%, while tech stocks fell 2.1%.
benzinga.com Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
benzinga.com Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level Amylyx Pharmaceuticals posts positive Phase 3 avexitide data for post-bariatric hypoglycemia. The company plans a 2026 FDA application.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity…
benzinga.com Market-Moving News for August 18th XOS: 140% | Xos shares are trading higher after the company announced that it has been awarded a prototype Other Transaction Agreement by the United States Air Force to develop and deliver a…- benzinga.com Amylyx Pharmaceuticals Says LUCIDITY Phase 3 Trial Met Its Primary Endpoint, Demonstrating 55% Reduction in Level 2 and Level 3 Hypoglycemic Events Vs. Placebo LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003)LUCIDITY met all…
benzinga.com Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket Flexsteel Industries Inc (FLXS) reported better-than-expected Q4 results, with shares jumping 9% in pre-market trading. Other gainers include PFSA, EJH, XOS, WETO, SGLY, VOGX, WFF, AMLX, and ENRD.…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
benzinga.com Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why Amylyx Pharmaceuticals shares are trading higher Monday after the company scheduled a Phase 3 trial results readout for this week.- benzinga.com Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
benzinga.com Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30 Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.- benzinga.com RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028 Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of…
benzinga.com Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26 Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.
benzinga.com This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.
benzinga.com Earnings Scheduled For March 3, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday 
benzinga.com This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday 
benzinga.com This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday 
benzinga.com Earnings Scheduled For May 8, 2025 
benzinga.com This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday 
benzinga.com Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For March 4, 2025
- benzinga.com Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
- benzinga.com Crude Oil Falls Over 1%; Willdan Group Shares Spike Higher U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday. The Dow traded up 0.21% to 38,874.05 while the NASDAQ fell 0.42% to 16,204.26. The S&P…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Market-Moving News for March 8th WLDN: 21% | Willdan Group shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 guidance above estimates. Also, the company secured a contract…
- benzinga.com Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Etsy, Inc.
- benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.